BASELINE HBSAG LEVELS PREDICT HBSAG LOSS IN HBEAG NEGATIVE BUT NOT IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA): AN INTERIM ANALYSIS

被引：0
|
作者：
Takkenberg, Bart [1 ,2 ]
Zaaijer, Hans L. [3 ,4 ]
de Niet, Annikki [1 ,2 ]
Weegink, Christine J. [1 ,2 ]
Terpstra, Valeska [5 ]
Koot, Maarten [7 ]
Dijkgraaf, Marcel [6 ]
Jansen, Peter L. [1 ,2 ]
Janssen, Harry L. [8 ]
Beld, Marcel [9 ]
Reesink, Hendrik W. [1 ,2 ]
机构：
[1] AMC Liver Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Med Microbiol & Karl Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
[4] Ctr Infect Dis & Immunol CINIMA, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[7] Sanquin, Dept Virus Diagnost Serv, Amsterdam, Netherlands
[8] Erasmus MC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[9] KIT Biomed Res, Amsterdam, Netherlands
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
488
引用
收藏
页码：536A / 537A
页数：2
相关论文
共 50 条
  • [1] HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 541A - 541A
  • [2] BASELINE HBSAG LEVEL AND ON-TREATMENT HBSAG AND HBV DNA DECLINE PREDICT SUSTAINED VIROLOGICAL RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 538A - 539A
  • [3] BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
    Takkenberg, B.
    Zaaijer, H.
    Weegink, C.
    Terpstra, V.
    Dijkgraaf, M.
    Jansen, P.
    Janssen, H.
    Beld, M.
    Reesink, H.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
  • [4] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
    Takkenberg, Bart
    Terpstra, Valeska
    Zaaijer, Hans L.
    Weegink, Christine J.
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2010, 52 (04) : 988A - 988A
  • [5] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR; AN INTERIM ANALYSIS
    Takkenberg, B.
    De Niet, A.
    Terpstra, V.
    Zaaijer, H.
    Weegink, C.
    Koot, M.
    Dijkgraaf, M.
    Jansen, P.
    Beld, M.
    Reesink, H.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S397 - S397
  • [6] ASSOCIATION BETWEEN TREATMENT OUTCOME AND RS12979860 POLYMORPHISM IN HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    de Niet, Annikki
    Benayed, Ryma
    Weegink, Christine J.
    Zaaijer, Hans L.
    Koot, Maarten
    Terpstra, Valeska
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Beld, Marcel
    Lopatin, Uri
    Reesink, Hendrik W.
    HEPATOLOGY, 2010, 52 (04) : 885A - 885A
  • [7] Association between Genotype and the HBsAg Levels at HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir or Peginterferon Alfa-2a
    Peng, Cheng-Yuan
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Lin, Chia-Hsin
    Chuang, Po-Heng
    Chen, Sheng-Hung
    HEPATOLOGY, 2014, 60 : 1121A - 1121A
  • [8] HIGH RATE OF HBSAG LOSS AND HBSAG SEROCONVERSION IN CHRONIC HEPATITIS B PATIENTS ON COMBINATION THERAPY WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA®): HBSAG TITER PREDICTS HBSAG LOSS OR SEROCONVERSION
    Takkenberg, Bart
    Zaaijer, Hans L.
    Weegink, Christine J.
    Terpstra, Volesko
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2008, 48 (04) : 1026A - 1027A
  • [9] BASELINE HBSAG AS PREDICTOR FOR HBSAG SEROCONVERSION IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: FINAL RESULTS OF A PROSPECTIVE OPEN LABEL STUDY
    Takkenberg, Bart
    de Niet, Annikki
    Zaaijer, Hans L.
    Weegink, Christine J.
    Terpstra, Valeska
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Rijckborst, Vincent
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2011, 54 : 1039A - 1040A
  • [10] ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Lau, G. K. K.
    Marcellin, P.
    Brunetto, M.
    Piratvisuth, T.
    Kapprell, H. -P
    Messinger, D.
    Popescu, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S333 - S333
12345